Association of anti-RNA polymerase III antibody and malignancy in Japanese patients with systemic sclerosis

Journal of Dermatology

Volumn 42, Issue 5, 2015, Pages 524-527

  Saigusa, Ryosuke ^a   Asano, Yoshihide ^a   Nakamura, Kouki ^a   Miura, Shunsuke ^a   Ichimura, Yohei ^a   Takahashi, Takehiro ^a   Toyama, Tetsuo ^a   Taniguchi, Takashi ^a   Noda, Shinji ^a   Aozasa, Naohiko ^a   Akamata, Kaname ^a   Sumida, Hayakazu ^a   Miyazaki, Miki ^a   Tamaki, Zenshiro ^a   Yanaba, Koichi ^a   Kuwano, Yoshihiro ^a   Sato, Shinichi ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

anti RNA polymerase III antibody; Japanese; malignancy; synchronous onset; systemic sclerosis

Indexed keywords

AUTOANTIBODY; CENTROMERE ANTIBODY; ENZYME ANTIBODY; RNA POLYMERASE III ANTIBODY; TOPOISOMERASE I ANTIBODY; UNCLASSIFIED DRUG; ANTINUCLEAR ANTIBODY; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; ETHNIC GROUP; FEMALE; HUMAN; JAPANESE (PEOPLE); MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NEOPLASM; PREVALENCE; RACE DIFFERENCE; SYSTEMIC SCLEROSIS; BLOOD; ETHNOLOGY; IMMUNOLOGY; INCIDENCE; JAPAN; NEOPLASMS;

ANTIBODIES, ANTINUCLEAR; DNA TOPOISOMERASES, TYPE I; FEMALE; HUMANS; INCIDENCE; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; RNA POLYMERASE III; SCLERODERMA, SYSTEMIC;

EID: 84928313956     PISSN: 03852407     EISSN: 13468138     Source Type: Journal    
DOI: 10.1111/1346-8138.12827     Document Type: Article

References (15)

1. Asano Y,. Future treatments in systemic sclerosis. J Dermatol 2010; 37: 54-70.
2. Shah AA, Rosen A, Hummers L, Wigley F, Casciola-Rosen L,. Close temporal relationship between onset of cancer and scleroderma in patients with RNA polymerase I/III antibodies. Arthritis Rheum 2010; 62: 2787-2795.
3. Airo P, Ceribelli A, Cavazzana I, Taraborelli M, Zingarelli S, Franceschini F,. Malignancies in Italian patients with systemic sclerosis positive for anti-RNA polymerase III antibodies. J Rheumatol 2011; 38: 1329-1334.
4. Nikpour M, Hissaria P, Byron J, et al,. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011; 13: R211.
5. Moinzadeh P, Fonseca C, Hellmich M, et al,. Association of anti-RNA polymerase III autoantibodies and cancer in scleroderma. Arthritis Res Ther 2014; 16: R53.
6. van den Hoogen F, Khanna D, Fransen J, et al,. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013; 72: 1747-1755.
7. Olesen AB, Svaerke C, Farkas DK, Sorensen HT,. Systemic sclerosis and the risk of cancer: a nationwide population-based cohort study. Br J Dermatol 2010; 163: 800-806.
8. Rosenthal AK, McLaughlin JK, Gridley G, Nyren O,. Incidence of cancer among patients with systemic sclerosis. Cancer 1995; 76: 910-914.
9. Joseph CG, Darrah E, Shah AA, et al,. Association of the autoimmune disease scleroderma with an immunologic response to cancer. Science 2014; 343: 152-157.
10. White RJ,. RNA polymerases I and III, growth control and cancer. Nat Rev Mol Cell Biol 2005; 6: 69-78.
11. DuPage M, Mazumdar C, Schmidt LM, Cheung AF, Jacks T,. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482: 405-409.
12. Matsushita H, Vesely MD, Koboldt DC, et al,. Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting. Nature 2012; 482: 400-404.
13. Buchbinder R, Forbes A, Hall S, Dennett X, Giles G,. Incidence of malignant disease in biopsy-proven inflammatory myopathy. A population-based cohort study. Ann Intern Med 2001; 134: 1087-1095.
14. Bernatsky S, Boivin JF, Joseph L, et al,. An international cohort study of cancer in systemic lupus erythematosus. Arthritis Rheum 2005; 52: 1481-1490.
15. Tatsis E, Reinhold-Keller E, Steindorf K, Feller AC, Gross WL,. Wegener's granulomatosis associated with renal cell carcinoma. Arthritis Rheum 1999; 42: 751-756.